Median Technologies Secures FDA 510(k) Clearance for eyonis® LCS, Accelerating U.S. Commercialization
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 23 2026
0mins
Should l Buy TEM?
Source: Newsfilter
- U.S. Market Access: Median Technologies has successfully secured FDA 510(k) clearance for eyonis® LCS, accelerating its commercialization efforts and expected to provide lung cancer screening services to approximately 14.5 million eligible individuals in the U.S., significantly enhancing the company's market share in cancer diagnostics.
- Reduction in Operating Loss: In 2025, Median Technologies achieved a 28% year-over-year reduction in operating loss, decreasing from €16.3 million in 2024 to €11.6 million in 2025, reflecting substantial improvements in cost control and operational efficiency, thereby boosting investor confidence.
- Record Order Backlog: As of March 31, 2026, Median's iCRO order backlog reached a record €79.8 million, representing a 4.2% increase from €76.6 million in December 2025, providing strong revenue visibility for the coming years.
- Stable Cash Flow: As of March 31, 2026, the company reported cash and cash equivalents of €14.0 million, with the potential to raise up to €44.4 million through the exercise of 2025 warrants, ensuring stable cash flow through year-end 2026 to support the execution of its strategic priorities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TEM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TEM
Wall Street analysts forecast TEM stock price to rise
9 Analyst Rating
4 Buy
5 Hold
0 Sell
Moderate Buy
Current: 49.470
Low
76.00
Averages
84.38
High
105.00
Current: 49.470
Low
76.00
Averages
84.38
High
105.00
About TEM
Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Healthcare Transformation: The Rise of Data-Driven Models
- Tempus AI's Market Potential: Tempus AI is collecting clinical and genomic data, with projected revenue of $1.27 billion in 2025, an 83% increase, positioning itself as a core player in precision medicine that enhances smart and precise medical decision-making.
- Recursion Pharmaceuticals' Innovative Model: Recursion Pharmaceuticals generated approximately $74.7 million in revenue last year through partnerships with Bayer and Roche, despite operating expenses exceeding $722 million, its innovative drug discovery model is poised to fundamentally change the dynamics of the pharmaceutical industry.
- Axsome Therapeutics' Rapid Growth: Axsome Therapeutics' Auvelity drug shows a rapid onset of action for major depressive disorder, reporting $191.2 million in revenue for Q1 2026, a 57% year-over-year increase, with FDA approval for Alzheimer's agitation potentially adding $2 billion in additional sales.
- Integration Trends in Future Healthcare: These three companies represent different layers of healthcare transformation, with Tempus AI focusing on data and personalization, Recursion Pharmaceuticals on automated drug discovery, and Axsome Therapeutics on enhancing treatment efficacy, collectively driving the healthcare system towards greater precision and efficiency.
See More
Tempus AI and Others Poised to Transform Precision Medicine
- Tempus AI's Growth Potential: Tempus AI is projected to reach $1.27 billion in revenue by 2025, an 83% increase from 2024, by collecting clinical and genomic data to assist doctors in making more precise treatment decisions, thereby positioning itself as a core player in precision medicine.
- Revolutionizing Drug Discovery: Recursion Pharmaceuticals aims to disrupt traditional drug discovery methods by integrating high-throughput automation and machine learning; despite operating expenses exceeding $722 million in 2025, its partnerships with Bayer and Roche generated approximately $74.7 million in revenue, indicating significant market potential.
- Rapid Advancement of Axsome Therapeutics: Axsome Therapeutics' Auvelity drug shows a rapid onset of action for major depressive disorder, with FDA approval for treating Alzheimer's agitation expected to generate an additional $2 billion in annual sales, highlighting its clinical advantage and market opportunity.
- Transformation of Future Healthcare Systems: These three companies represent different layers of the healthcare industry's evolution, combining data-driven and precision treatment trends, and by 2030, the winners will be those who own the data, accelerate discovery, and deliver real outcomes, fundamentally reshaping the healthcare landscape.
See More
Tempus AI Upsizes Private Offering to $400M in Convertible Notes
- Upsized Offering: Tempus AI has increased its convertible notes offering from the initial $350 million to $400 million, reflecting strong market confidence in its financing needs and potentially enhancing the company's capital structure.
- Clear Use of Proceeds: The expected net proceeds of approximately $384.1 million will primarily be used to repay $307.7 million of outstanding loans, indicating proactive measures in optimizing financial burdens while also supporting future acquisitions and investments.
- Investor Option: Initial purchasers have a 13-day option to buy up to an additional $60 million in convertible notes, which may attract more investor participation and further bolster market confidence.
- Maturity Timeline: The notes will mature on May 15, 2032, unless converted, redeemed, or repurchased earlier, providing investors with a longer investment horizon that may appeal to those seeking long-term returns.
See More
Tempus AI Prices $400 Million Convertible Notes Offering
- Increased Offering Size: Tempus AI announced the pricing of $400 million in 0.00% convertible senior notes, up from the previously announced $350 million, indicating strong market confidence in its financing needs.
- Clear Use of Proceeds: The estimated net proceeds of approximately $384.1 million will be used to repay $307.7 million in loans and cover other expenses, while also providing funds for future acquisitions and strategic investments, enhancing the company's financial flexibility.
- Flexible Conversion Terms: The initial conversion rate of 14.4388 shares per $1,000 principal amount of notes represents a conversion premium of about 40%, offering an attractive proposition for investors that may drive stock price appreciation.
- Risk Management Measures: Tempus entered into capped call transactions with initial purchasers to mitigate potential dilution of equity, which is expected to positively impact future stock performance and bolster investor confidence.
See More
Tempus AI Prices $400 Million Convertible Notes Offering
- Increased Offering Size: Tempus AI announced the pricing of $400 million in 0.00% Convertible Senior Notes, up from the previously announced $350 million, indicating strong market demand for its financing needs.
- Clear Use of Proceeds: The estimated net proceeds of approximately $384.1 million will be used to repay $307.7 million in outstanding senior secured loans and related fees, enhancing financial stability and supporting future strategic investments.
- Flexible Conversion Terms: The initial conversion rate is set at 14.4388 shares of common stock per $1,000 principal amount, with a conversion premium of about 40%, providing an attractive option for investors while laying the groundwork for potential stock price appreciation.
- Risk Management Measures: Tempus entered into capped call transactions with initial purchasers to mitigate potential dilution of equity, ensuring minimal impact on shareholders during note conversions and bolstering market confidence.
See More
Tempus AI Reports Strong Q1 2026 Earnings with Revenue Growth
- Significant Revenue Growth: Tempus AI reported Q1 revenue of $348.1 million, reflecting over 36% year-over-year growth, indicating the company's strong market performance and sustained growth potential.
- Strong Diagnostic Business: Diagnostic revenue reached $261.1 million, representing nearly 35% growth, with the oncology segment showing unit growth of about 28%, highlighting the company's competitiveness and rising market demand in critical areas.
- Outstanding Data Business Performance: The data and applications segment generated $87 million in revenue, marking a 40.5% year-over-year increase, with bookings exceeding $100 million for the third consecutive quarter, demonstrating strong customer demand for the company's data solutions.
- Optimistic Full-Year Outlook: The company raised its full-year revenue guidance to a range of $1.59 billion to $1.6 billion, with expected adjusted EBITDA of approximately $65 million, reflecting management's confidence in future growth and market opportunities.
See More
Healthcare Transformation: The Rise of Data-Driven Models
- Tempus AI's Market Potential: Tempus AI is collecting clinical and genomic data, with projected revenue of $1.27 billion in 2025, an 83% increase, positioning itself as a core player in precision medicine that enhances smart and precise medical decision-making.
- Recursion Pharmaceuticals' Innovative Model: Recursion Pharmaceuticals generated approximately $74.7 million in revenue last year through partnerships with Bayer and Roche, despite operating expenses exceeding $722 million, its innovative drug discovery model is poised to fundamentally change the dynamics of the pharmaceutical industry.
- Axsome Therapeutics' Rapid Growth: Axsome Therapeutics' Auvelity drug shows a rapid onset of action for major depressive disorder, reporting $191.2 million in revenue for Q1 2026, a 57% year-over-year increase, with FDA approval for Alzheimer's agitation potentially adding $2 billion in additional sales.
- Integration Trends in Future Healthcare: These three companies represent different layers of healthcare transformation, with Tempus AI focusing on data and personalization, Recursion Pharmaceuticals on automated drug discovery, and Axsome Therapeutics on enhancing treatment efficacy, collectively driving the healthcare system towards greater precision and efficiency.
See More
Tempus AI and Others Poised to Transform Precision Medicine
- Tempus AI's Growth Potential: Tempus AI is projected to reach $1.27 billion in revenue by 2025, an 83% increase from 2024, by collecting clinical and genomic data to assist doctors in making more precise treatment decisions, thereby positioning itself as a core player in precision medicine.
- Revolutionizing Drug Discovery: Recursion Pharmaceuticals aims to disrupt traditional drug discovery methods by integrating high-throughput automation and machine learning; despite operating expenses exceeding $722 million in 2025, its partnerships with Bayer and Roche generated approximately $74.7 million in revenue, indicating significant market potential.
- Rapid Advancement of Axsome Therapeutics: Axsome Therapeutics' Auvelity drug shows a rapid onset of action for major depressive disorder, with FDA approval for treating Alzheimer's agitation expected to generate an additional $2 billion in annual sales, highlighting its clinical advantage and market opportunity.
- Transformation of Future Healthcare Systems: These three companies represent different layers of the healthcare industry's evolution, combining data-driven and precision treatment trends, and by 2030, the winners will be those who own the data, accelerate discovery, and deliver real outcomes, fundamentally reshaping the healthcare landscape.
See More
Tempus AI Upsizes Private Offering to $400M in Convertible Notes
- Upsized Offering: Tempus AI has increased its convertible notes offering from the initial $350 million to $400 million, reflecting strong market confidence in its financing needs and potentially enhancing the company's capital structure.
- Clear Use of Proceeds: The expected net proceeds of approximately $384.1 million will primarily be used to repay $307.7 million of outstanding loans, indicating proactive measures in optimizing financial burdens while also supporting future acquisitions and investments.
- Investor Option: Initial purchasers have a 13-day option to buy up to an additional $60 million in convertible notes, which may attract more investor participation and further bolster market confidence.
- Maturity Timeline: The notes will mature on May 15, 2032, unless converted, redeemed, or repurchased earlier, providing investors with a longer investment horizon that may appeal to those seeking long-term returns.
See More
Tempus AI Prices $400 Million Convertible Notes Offering
- Increased Offering Size: Tempus AI announced the pricing of $400 million in 0.00% convertible senior notes, up from the previously announced $350 million, indicating strong market confidence in its financing needs.
- Clear Use of Proceeds: The estimated net proceeds of approximately $384.1 million will be used to repay $307.7 million in loans and cover other expenses, while also providing funds for future acquisitions and strategic investments, enhancing the company's financial flexibility.
- Flexible Conversion Terms: The initial conversion rate of 14.4388 shares per $1,000 principal amount of notes represents a conversion premium of about 40%, offering an attractive proposition for investors that may drive stock price appreciation.
- Risk Management Measures: Tempus entered into capped call transactions with initial purchasers to mitigate potential dilution of equity, which is expected to positively impact future stock performance and bolster investor confidence.
See More
Tempus AI Prices $400 Million Convertible Notes Offering
- Increased Offering Size: Tempus AI announced the pricing of $400 million in 0.00% Convertible Senior Notes, up from the previously announced $350 million, indicating strong market demand for its financing needs.
- Clear Use of Proceeds: The estimated net proceeds of approximately $384.1 million will be used to repay $307.7 million in outstanding senior secured loans and related fees, enhancing financial stability and supporting future strategic investments.
- Flexible Conversion Terms: The initial conversion rate is set at 14.4388 shares of common stock per $1,000 principal amount, with a conversion premium of about 40%, providing an attractive option for investors while laying the groundwork for potential stock price appreciation.
- Risk Management Measures: Tempus entered into capped call transactions with initial purchasers to mitigate potential dilution of equity, ensuring minimal impact on shareholders during note conversions and bolstering market confidence.
See More
Tempus AI Reports Strong Q1 2026 Earnings with Revenue Growth
- Significant Revenue Growth: Tempus AI reported Q1 revenue of $348.1 million, reflecting over 36% year-over-year growth, indicating the company's strong market performance and sustained growth potential.
- Strong Diagnostic Business: Diagnostic revenue reached $261.1 million, representing nearly 35% growth, with the oncology segment showing unit growth of about 28%, highlighting the company's competitiveness and rising market demand in critical areas.
- Outstanding Data Business Performance: The data and applications segment generated $87 million in revenue, marking a 40.5% year-over-year increase, with bookings exceeding $100 million for the third consecutive quarter, demonstrating strong customer demand for the company's data solutions.
- Optimistic Full-Year Outlook: The company raised its full-year revenue guidance to a range of $1.59 billion to $1.6 billion, with expected adjusted EBITDA of approximately $65 million, reflecting management's confidence in future growth and market opportunities.
See More
